ライフサイエンスコーパス: mycosis fungoides

1 specially in Sezary syndrome and transformed mycosis fungoides.

2 ad chronic myelogenous leukemia, and one had mycosis fungoides.

3 tes the results to skin stage and outcome in mycosis fungoides.

4 10q and MSI in advanced cutaneous stages of mycosis fungoides.

5 arge proportion of patients with early stage mycosis fungoides.

6 ssessment of peripheral blood involvement in mycosis fungoides.

7 feature of the large-cell transformation of mycosis fungoides.

8 usly as a single dose to eight patients with mycosis fungoides.

9 ype may contribute to disease progression in mycosis fungoides.

10 was associated with an older age of onset of mycosis fungoides.

11 all of which were from the 44 patients with mycosis fungoides (10/44 patients; 23%).

12 s antibody (1) had clinical efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low

13 n 18 patients (25%), including 12 of 57 with mycosis fungoides (21%) and six of 16 with Sezary syndro

14 Seven patients (44%) had cutaneous (all mycosis fungoides); 4 (25%) had peripheral T cell not ot

15 as found to be more prevalent in tumor stage mycosis fungoides (47%) than early stage disease (20%) a

16 tificates for two such cancers, melanoma and mycosis fungoides (a cutaneous lymphoma), using routinel

17 ease that recapitulates many key features of mycosis fungoides, a common variant of cutaneous T-cell

18 pendent prognostic variable in patients with mycosis fungoides after correcting for age, skin, and ly

19 the 54 samples (24%), 12 from patients with mycosis fungoides and 1 from a patient with Sezary syndr

20 have analyzed 51 samples from patients with mycosis fungoides and 15 with Sezary syndrome using meth

21 uding losses on 9p21 in 16% of patients with mycosis fungoides and 46% with Sezary syndrome.

22 lic loss was present in 45% of patients with mycosis fungoides and 67% with Sezary syndrome.

23 tested SS patients but not in patients with mycosis fungoides and atopic dermatitis or HD.

24 Mycosis fungoides and its leukemic variant, Sezary syndr

25 Mycosis fungoides and Sezary syndrome (MF/SS) are rare i

26 common in both early and advanced stages of mycosis fungoides and Sezary syndrome and that these gen

27 Mycosis fungoides and Sezary syndrome are the most commo

28 Mycosis fungoides and Sezary syndrome are two major form

29 Although the aetiologies of mycosis fungoides and Sezary syndrome are unknown, impor

30 Mycosis fungoides and Sezary syndrome comprise the major

31 approximately 30% of patients with advanced mycosis fungoides and Sezary syndrome cutaneous T-cell l

32 aneous T-cell lymphoma (CTCL), including the mycosis fungoides and Sezary syndrome forms of the disea

33 ined lesional skin biopsy specimens from 113 mycosis fungoides and Sezary Syndrome patients for activ

34 lly reverse or suppress the abnormalities of mycosis fungoides and Sezary syndrome to the point at wh

35 ous T-cell lymphoma (CTCL), particularly the mycosis fungoides and Sezary syndrome variants, has been

36 276 patients with cutaneous T cell lymphoma (mycosis fungoides and Sezary syndrome) using 2,4-dinitro

37 oproliferative processes, mainly composed of mycosis fungoides and Sezary syndrome, the aggressive fo

38 Discoveries regarding the pathophysiology of mycosis fungoides and Sezary syndrome, the two most comm

39 candidate tumor suppressor genes involved in mycosis fungoides and Sezary syndrome.

40 h cutaneous T-cell lymphoma (CTCL) including mycosis fungoides and Sezary syndrome.

41 ctor receptor TNFR2, in 18% of patients with mycosis fungoides and Sezary syndrome.

42 subtypes of the disease, the most common are mycosis fungoides and Sezary syndrome.

43 logy of cutaneous T-cell lymphoma, including mycosis fungoides and Sezary syndrome.

44 ous T-cell lymphoma with special emphasis on mycosis fungoides and Sezary syndrome.

45 Mycosis fungoides and the Sezary syndrome represent a he

46 g, prognosis, and treatment of patients with mycosis fungoides and the Sezary syndrome.

47 ung, and unknown primary tumors, meningioma, mycosis fungoides, and myeloid leukemia.

48 lar lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respe

49 goid, transient acantholytic dermatosis, and mycosis fungoides, and should be considered in elderly p

50 Sezary syndrome and mycosis fungoides are related chronic lymphoproliferativ

51 mas, with particular emphasis on tumor stage mycosis fungoides, as it is in these cases that p53 over

52 PTEN may be important in the pathogenesis of mycosis fungoides, but our data imply that this gene is

53 The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and s

54 Malignant melanoma and mycosis fungoides (cutaneous T cell lymphoma) are rare m

55 from a Macaca nemestrina with CD8(+) T-cell mycosis fungoides-cutaneous T-cell lymphoma.

56 Thus, lesions clinically suspicious for mycosis fungoides, especially those that have failed chr

57 s suggest that patients with folliculotropic mycosis fungoides (FMF) have a worse prognosis than pati

58 aviolet B-related step in the progression of mycosis fungoides from plaque to tumor-stage disease.

59 its total absence in PBLs from patients with mycosis fungoides, inflammatory cutaneous or hematologic

60 Mycosis fungoides is a cutaneous malignancy usually foun

61 0.02%, gel in the treatment of patients with mycosis fungoides is effective and safe.

62 mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fungoides (MF) (9% [n = 8]).

63 (CTCL) comprising 10 cases with early-stage mycosis fungoides (MF) and 10 cases with late-stage MF o

64 SHV/HHV-8 is involved in the pathogenesis of mycosis fungoides (MF) and related disorders, we used a

65 Transformed mycosis fungoides (MF) and Sezary syndrome (SS) are curr

66 Mycosis fungoides (MF) and Sezary syndrome (SS) are the

67 ective retinoid that can induce apoptosis of mycosis fungoides (MF) and Sezary syndrome (SS) cells.

68 umor, node, metastases (TNM) system used for mycosis fungoides (MF) and Sezary syndrome (SS) is not a

69 CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sezary syndrome (SS) is quite

70 ogy and diagnostic techniques as pertains to mycosis fungoides (MF) and Sezary syndrome (SS) since th

71 ic treatment options exist for patients with mycosis fungoides (MF) and Sezary syndrome (SS), but no

72 MTAP in cutaneous T-cell lymphoma subgroups, mycosis fungoides (MF) and Sezary syndrome (SS), is unkn

73 Mycosis fungoides (MF) and Sezary syndrome (SS), the maj

74 treatment of CTCL, with specific emphasis on mycosis fungoides (MF) and Sezary syndrome (SS).

75 months) in heavily pretreated patients with mycosis fungoides (MF) and Sezary syndrome (SS).

76 xyadenosine (2-CdA) therapy in patients with mycosis fungoides (MF) and the Sezary syndrome (SS).

77 Sezary syndrome (SS) and tumor-stage mycosis fungoides (MF) are generally incurable with curr

78 Neoplastic T cells in mycosis fungoides (MF) are resistant to apoptotic agents

79 Mycosis fungoides (MF) is a cutaneous T-cell lymphoma ch

80 Mycosis fungoides (MF) is a low-grade lymphoma of cluste

81 Large cell transformation (LCT) in mycosis fungoides (MF) is generally associated with an a

82 Mycosis fungoides (MF) is the most common form of cutane

83 Mycosis fungoides (MF) is the most common primary cutane

84 Mycosis fungoides (MF) is the most common primary cutane

85 Mycosis fungoides (MF) is the most common subtype of cut

86 Mycosis fungoides (MF) is the most frequent form of cuta

87 Mycosis fungoides (MF) is the most frequent manifestatio

88 Although mycosis fungoides (MF) is typically an indolent disease,

89 Although mycosis fungoides (MF) may arise through persistent anti

90 e cell lymphoma (ALCL) of 2 patients and the mycosis fungoides (MF) of 2 other patients.

91 hrough stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical respon

92 Because patients with mycosis fungoides (MF) usually do not have such antibodi

93 ND1/BCL1 expression in 18 of 30 SS, 10 of 23 mycosis fungoides (MF), and three of 10 primary cutaneou

94 patients with the cutaneous T-cell lymphoma, mycosis fungoides (MF), are seronegative for human T-cel

95 catter T (T(HS)) cells were CD4(+) in CD4(+) mycosis fungoides (MF), CD8(+) in CD8(+) MF, and contain

96 The histopathologic diagnosis of mycosis fungoides (MF), even when clinical manifestation

97 mphoma (CTCL), including Sezary syndrome and mycosis fungoides (MF), is poor.

98 sis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is unclear.

99 (CTCL) may present with eczematous lesions, mycosis fungoides (MF), or as exfoliative erythroderma w

100 patients with a diagnosis of CTCL, including mycosis fungoides (MF), Sezary syndrome (SS), or CTCL no

101 The pathogenesis of mycosis fungoides (MF), the most common cutaneous T-cell

102 f inflammatory cytokines in 12 patients with mycosis fungoides (MF), the most common variant of CTCL.

103 a worse prognosis than patients with classic mycosis fungoides (MF).

104 A skin biopsy confirmed mycosis fungoides (MF).

105 explored this strategy in a second disease: mycosis fungoides (MF).

106 proliferative disorders (CD30CLPD) and early mycosis fungoides (MF).

107 SS) and primarily cutaneous variants such as mycosis fungoides (MF).

108 od lymphocyte cultures from 19 patients with mycosis fungoides (MF)/Sezary syndrome (SS) stimulated w

109 Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sezary syndr

110 ients with treatment refractory CD4(+) CTCL (mycosis fungoides [MF], n = 38; Sezary syndrome [SS], n

111 .1% in Sezary syndrome (n = 17) and 28.6% in mycosis fungoides (n = 21).

112 oma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n

113 osity was found in over 10% of patients with mycosis fungoides on 9p, 10q, 1p, and 17p and was presen

114 e enrolled adult patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large-

115 s had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sezary syndrome (14 with large-cell

116 id) in persistent, progressive, or recurrent mycosis fungoides or Sezary syndrome (MF/SS) cutaneous t

117 ve therefore studied 76 patients with either mycosis fungoides or Sezary syndrome for abnormalities o

118 uppression, such that patients with advanced mycosis fungoides or Sezary syndrome have been compared

119 utaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sezary syndrome, who had received n

120 DLBCL: OR(allelic) = 1.12, P(trend) = 0.006; mycosis fungoides: OR(allelic) = 1.44, P(trend) = 0.015)

121 haracteristically slow, we hypothesized that mycosis fungoides originates from an accumulation of lym

122 In the subset of patients with mycosis fungoides, P53 mutations were identified in six

123 bility, a study on specimens of relatives of mycosis fungoides patients (MFR) was begun.

124 quence of hMLH1 promoter hypermethylation in mycosis fungoides patients and may prevent transcription

125 in 21/35 (60%) SS patients and in 3/8 (38%) mycosis fungoides patients, all of whom had clonal blood

126 Sezary syndrome and 5 with rapidly enlarging mycosis fungoides plaques or tumors.

127 Fifty-one mycosis fungoides samples were analyzed for microsatelli

128 Eligibility included mycosis fungoides, Sezary syndrome, or primary cutaneous

129 ll documented in a subgroup of patients with mycosis fungoides/Sezary syndrome (MF/SS).

130 BMC is not due to an intrinsic defect in the mycosis fungoides/Sezary syndrome patients' immune acces

131 ns and outcomes of a subset of patients with mycosis fungoides/Sezary syndrome who were treated with

132 d cases of cutaneous T cell lymphoma (CTCL) (mycosis fungoides/Sezary syndrome) undergo large cell tr

133 f 31 cutaneous T-cell lymphoma (CTCL) cases (mycosis fungoides/Sezary syndrome, SS) as well as in 5 o

134 e-agent lenalidomide in advanced, refractory mycosis fungoides/Sezary syndrome.

135 ients with Sezary syndrome (SS), transformed mycosis fungoides (T-MF), and cutaneous anaplastic large

136 evels of TOX were significantly increased in mycosis fungoides, the most common type of cutaneous T-c

137 We also included tissue from two cases of mycosis fungoides, three normal skin biopsies, and three

138 Eighteen cases of early mycosis fungoides were compared with 18 cases of eczemat

139 that only 60% of the deaths attributable to mycosis fungoides were so certified.

140 erythroderma or Sezary syndrome and 11 with mycosis fungoides, were studied for the occurrence of st

141 oss on 1p and 9p were found in all stages of mycosis fungoides, whereas losses on 17p and 10q were li

142 In total, 260 patients with stage IA to IIA mycosis fungoides who had not used topical mechlorethami

143 MSI and disease progression in patients with mycosis fungoides, with 6 of 15 (40%) patients with MSI